News Feature

In our first monthly round up of the year we explore the big stories from 2020, including key biopharma deals, FDA approvals and IPOs, as well as the extraordinary impact of COVID-19 on science throughout an unusual 12 months.

A string of billion dollar deals, many focused on the development of oncology therapeutics, rounded off an extraordinary year.

COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.

Biopharma Dealmakers’ monthly round-up continues exploring the most significant biopharma deals of the previous month.

After a decade of uncertainty, a trio of clinical trial successes in 2020 is spurring enthusiasm about the potential for effectively treating disease via manipulation of the gut microbiome.

The maturation of oligonucleotide and gene therapies, and the birth of the gene editing revolution, are spurring innovation in the cardiovascular and metabolic disease space.

The COVID-19 pandemic dealt a blow to the deals landscape in early 2020, but the sector bounced back.

In our second monthly digest of ‘business of science’ articles from Springer Nature research journals, magazines and supplements, we delve into the history of cystic fibrosis research, celebrate two Nobel prize–winning CRISPR gene editing pioneers and examine big pharma’s interest in antibody–drug conjugates and exosomes.

Biopharma Dealmakers’ monthly round-up explores the most significant biopharma deals of the previous month.

In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.

Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.

The market for drugs to treat central nervous system disorders is set for growth, supported by the continued strength of therapies for multiple sclerosis.

Partnerships are playing an important role in the pursuit of coronavirus-specific antibodies for diagnostics and therapies for COVID‑19.

Optimization of CAR-T cell technology and application of other immune cell types such as NK cells are tackling the efficacy, cost and logistical challenges of cell therapies for cancer.

After a slow start to the year, dealmaking for the rest of 2020 is likely to be profoundly affected by the COVID‑19 pandemic.

The next-generation therapeutics space has continued to progress on several fronts in the past 12 months, but this could be set to change as the industry copes with the COVID‑19 crisis.

History has shown that collaborative efforts can have a crucial role in combating viral outbreaks such as the current coronavirus pandemic.

While dealmaking in oncology continued to feature immunotherapies—particularly multi-targeted agents—there was also diversification, with prominent deals for precision medicine and novel platform technologies.

M&A activity in the biopharma industry continued to boom last year, with more than 200 deals collectively worth over $200 billion.

Applications are now open for The Spinoff Prize — a new award for early stage university spinoff companies from around the world!